Plasmodium vivax pre-erythrocytic vaccines.
Parasitol Int
; 84: 102411, 2021 Oct.
Article
em En
| MEDLINE
| ID: mdl-34166786
ABSTRACT
An estimated 229 million cases of malaria occurred worldwide in 2019. Both, Plasmodium falciparum and P. vivax are responsible for most of the malaria disease burden in the world. Despite difficulties in obtaining an accurate number, the global estimates of cases in 2019 are approximately 229 million of which 2.8% are due to P. vivax, and the total number of malaria deaths are approximately 409 million. Regional elimination or global eradication of malaria will be a difficult task, particularly for P. vivax due to the particular biological features related to the hypnozoite, leading to relapse. Countries that have shown successful episodes of a decrease in P. falciparum malaria, are left with remaining P. vivax malaria cases. This is caused by the mechanism that the parasite has evolved to remain dormant in the liver forming hypnozoites. Furthermore, while clinical trials of vaccines against P. falciparum are making fast progress, a very different picture is seen with P. vivax, where only few candidates are currently active in clinical trials. We discuss the challenge that represent the hypnozoite for P. vivax vaccine development, the potential of Controlled Human Malaria Challenges (CHMI) and the leading vaccine candidates assessed in clinical trials.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Contexto em Saúde:
3_ND
/
4_TD
Problema de saúde:
3_malaria
/
3_neglected_diseases
/
4_malaria
Assunto principal:
Plasmodium vivax
/
Malária Vivax
/
Vacinas Antimaláricas
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Parasitol Int
Assunto da revista:
PARASITOLOGIA
Ano de publicação:
2021
Tipo de documento:
Article